1. In adult male patients with spermatogenic failure (SPGF), letrozole (Femara) is well tolerated and associated with significantly greater upgrade rates ...
Click to read this study in The Lancet Oncology.
1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6 ...
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Network Open.
Click to read this study in The Lancet Oncology.
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
Click here to read this study in JAMA Oncology.
Click to read this study in JAMA Oncology.
Click to read the study in The Lancet Oncology.
